BRIEF-Pfizer presents results from two Phase 3 trumenba studies

viernes 13 de mayo de 2016 06:45 GYT

May 13 (Reuters) - Pfizer Inc

* Pfizer presents results from two Phase 3 trumenba(meningococcal Group B vaccine) studies at the European society for paediatric infectious diseases meeting

* Secondary data support that trumenba protects against additional meningococcal serogroup b strains

* Phase 3 data support additional global regulatory submissions for trumenba

* Phase 3 data also supports planned U.S. supplement to request conversion of accelerated approval to traditional approval for trumenba

* The two studies, one in adolescents and one in young adults, met all primary immunogenicity endpoints Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)